News

Celebrating Dr. Prithvi Ramtohul: Ramin Tadayoni Award Winner

Celebrating Dr. Prithvi Ramtohul: Ramin Tadayoni Award Winner

Oculis Champions the Future of Retinal Research

Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a forefront biopharmaceutical company known for its commitment to advancing treatments for ophthalmic and neuro-ophthalmic diseases, has made a significant announcement regarding the Ramin Tadayoni Award for 2025. This recognition, crafted in alliance with EURETINA, champions new talent in the field of retina research.

A Tribute to Visionary Leaders

The Ramin Tadayoni Award was created to honor the legacy of Professor Ramin Tadayoni, who was not just a leader in retinal science but a valued figure within Oculis. This award aims to uplift the next wave of ophthalmologists by rewarding outstanding postgraduate scholars dedicated to retinal studies.

2025 Award Recipient: A Bright Star

In the current selection, Prithvi Ramtohul, M.D., stands out for his remarkable achievements in retinal imaging and various retinal diseases. He is actively researching the plasticity of neuronal excitability within retinal ganglion cells, pushing the boundaries of existing knowledge in the field.

A Word from EURETINA

Anat Loewenstein, M.D., President of EURETINA, shared heartfelt appreciation towards all applicants, calling their entries “remarkable”. She expressed her joy in awarding Dr. Ramtohul. This accolade serves as both recognition and motivation, aligning with Dr. Ramtohul's goal to delve into the cellular dynamics of conditions such as amblyopia, aiming to develop innovative therapeutic strategies that could significantly elevate patient care.

Oculis Highlights Commitment

Dr. Riad Sherif, CEO of Oculis, extended his congratulations to Dr. Ramtohul, commending both his accomplishments and the ongoing partnership with EURETINA in promoting research excellence. Dr. Sherif emphasized the importance of honoring Professor Tadayoni’s legacy and continuing to foster research that has the potential to change lives.

Dr. Prithvi Ramtohul's Journey

Currently, Dr. Ramtohul is involved with the Retinal Division at Aix-Marseille University Hospital, where he serves as a physician while pursuing his Ph.D. at INSERM-AMU in Marseille, France. His academic journey includes a notable residency in ophthalmology and fellowship training under the guidance of Professor Tadayoni in Paris. Additionally, he has enriched his experience through a fellowship with Professor K. Bailey Freund in New York, focusing on retinal research.

Impactful Contributions

Dr. Ramtohul’s academic portfolio boasts 111 peer-reviewed studies, detailing innovative findings such as new OCT imaging markers and identifying rare retinal diseases. His research exploits multimodal imaging techniques to deepen the understanding of retinal pathophysiology, a vital step forward in enhancing treatment methods. His work continues to garner accolades, including the Gabriel Coscas Award and invitations to numerous prestigious conferences worldwide.

About Oculis and Its Mission

Oculis is dedicated to pushing the boundaries of treatment in ophthalmic conditions and affirms its commitment through an impressive clinical pipeline. Among its key products are OCS-01, a pivotal eye drop aimed at treating diabetic macular edema; Privosegtor (OCS-05), engineered for acute optic neuritis; and Licaminlimab (OCS-02), which aims to personalize approaches in dry eye disease. With headquarters in Switzerland and a dynamic presence in the U.S. and Iceland, Oculis thrives under seasoned leadership and has garnered support from prominent healthcare investors.

Further Information

For additional insights about Oculis and its endeavors, you can explore the company’s official website.

Oculis Contacts

Contact Ms. Sylvia Cheung, CFO for inquiries at sylvia.cheung@oculis.com.

Investor Relations

For investor-related queries, reach out to Corey Davis, Ph.D. at LifeSci Advisors, cdavis@lifesciadvisors.com.

Media Relations

For media inquiries, get in touch with ICR Healthcare: oculis@icrhealthcare.com.

Frequently Asked Questions

What is the Ramin Tadayoni Award?

This award recognizes outstanding postgraduate scholars in retinal research, commemorating the legacy of Professor Ramin Tadayoni.

Who is the 2025 award recipient?

The 2025 award is presented to Dr. Prithvi Ramtohul for his contributions to retinal imaging and diseases.

What are Dr. Ramtohul’s research interests?

Dr. Ramtohul focuses on neuronal excitability in retinal ganglion cells and aims to innovate treatment strategies for retinal conditions.

What does Oculis specialize in?

Oculis specializes in innovative biopharmaceutical treatments for ophthalmic and neuro-ophthalmic diseases.

How can I contact Oculis?

You can reach Oculis through their official email for various inquiries or visit their website for more information.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AXON Revenue Forecast Cut Spurs Legal Investigation

Updated Category News Views 87

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

Continue Reading
West Virginia Water Gains: Central Grove Upgrade Begins

Updated Category News Views 98

Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...

Continue Reading
ANDPAD Shines in Asia's 2026 Growth Company Awards

Updated Category News Views 165

AI Takes Center Stage in Construction Ever seen AI shake a dusty old industry to its core? Well, if you haven't, ANDPAD is doing just that in construction, making waves across Asia. Look, when a company like ANDPAD snags a spot in the 'NextGen Tech 30 2026,' you pay attention. That's a glitzy award for the movers and shakers in tech, and these folks are doing some serious...

Continue Reading
Senstar Boasts Robust Q3 Growth Amid Global Demand

Updated Category News Views 129

A Standout Quarter for Senstar Technologies How often do you see a company jumping 37% in revenue year-over-year? Not every day, that’s for sure. But that's exactly what's happening with Senstar Technologies Corporation (NASDAQ: SNT). For the third quarter of 2026, they've pulled in $13.1 million compared to last year’s $9.5 million. And that's not just some fluke –...

Continue Reading
Mobile Health Program Drives Down Hospital Visits

Updated Category News Views 61

The wheels are literally in motion in South Broward, with Memorial Healthcare System's Mobile Health Program taking healthcare to the doorstep of thousands. This killer initiative slashed hospital admissions by a nifty 62% among its users in 2025, and they ain't slowing down in 2026. Talk about bringing the doctor to the streets and changing lives! Healthcare On Wheels:...

Continue Reading
Kuaishou Prepares for Q3 Financial Reveals—November 19

Updated Category News Views 144

We're watching the countdown to November 19, 2026, when Kuaishou Technology plans to spill the beans on its third-quarter earnings. Now, the clock's ticking not just in Beijing but across the financial landscape, as investors everywhere hold their breaths, hoping for some juicy financial insights from this colossal social platform. It's a heavyweight showdown any stock...

Continue Reading
Brookdale Shows Recovery with Improved Q3 2026 Results

Updated Category News Views 25

Cracking Open Brookdale's Q3 2026 Numbers: A Mixed Bag You know, there's something oddly satisfying about net losses shrinking like a cheap wool sweater in a hot wash. Brookdale Senior Living's third quarter results show just that. We're looking at a net loss of $13.9 million, a big step up from the towering $114.7 million nosedive a year ago. Yeah, it's still a loss, but...

Continue Reading
Frederick's VFW Post Thrives with New Facility Launch

Updated Category News Views 78

The Power of Building a Legacy There I was, watching the home the VFW built not just with nails and beams, but conviction. In a world where construction and legacy often don't speak the same language, the Frederick VFW Post 3285 is flipping the script. We're looking at a story about real, tangible impact—not in the P&Ls but in actual lives. Brick by Brick: A...

Continue Reading
Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

Updated Category News Views 92

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Continue Reading
FDA Greenlights Halozyme's Cancer Treatment Breakthrough

Updated Category News Views 109

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Continue Reading

Top 5 Most Recently Viewed Articles

Harris & Harris Group Navigates Market Challenges as TURN Hits Low

Updated Category News Views 193

Market Challenges Impacting Harris & Harris Group In the current challenging market landscape, shares of Harris & Harris Group, Inc. (NASDAQ: TURN) have hit a 52-week low of $3.3. This investment firm, known for its venture capital endeavors, has encountered substantial difficulties over the past year, evidenced by a notable decline of 19.76%. Such a downturn reflects...

Continue Reading
Purdue Innovates Fast Lead Detection for Healthier Communities

Updated Category News Views 214

Innovative Approaches for Lead Exposure Detection Lead exposure can have serious consequences on health, and it is crucial to have effective methods for its detection. A team at Purdue University has pioneered transformative technologies that streamline the process of measuring lead exposure in blood and bone tissues. The innovations developed offer significant benefits...

Continue Reading
Devon Energy's Upcoming Fireside Chat at J.P. Morgan Conference

Updated Category News Views 195

Devon Energy Engages with Investors at J.P. Morgan Conference Devon Energy Corp. (NYSE: DVN) is gearing up for an exciting opportunity to engage directly with investors. Clay Gaspar, the company’s President and CEO, will be participating in a fireside chat at the prestigious J.P. Morgan Energy, Power, Renewables & Mining Conference. This event promises to be informative...

Continue Reading
Spanish Stock Market Dynamics: Key Highlights and Trends

Updated Category News Views 384

Recent Developments in the Spanish Stock Market The Spanish stock market experienced a downturn recently, closing lower amid notable sectoral losses. The primary sectors that faced declines included Telecoms & IT, Building & Construction, and Chemical, Petroleum & Plastic. These pullbacks adversely affected many stocks, particularly within the IBEX 35 index. IBEX 35...

Continue Reading
Oppenheimer Keeps GDEV Stock Rating Amid Growth Potential

Updated Category News Views 73

Oppenheimer Maintains Perform Rating on GDEV Inc. Oppenheimer has decided to keep its Perform rating on shares of GDEV Inc. (NASDAQ: GDEV), focusing on the exciting growth avenues being explored for the company's PG3 game. The firm notes that while PG3 currently constitutes less than 10% of GDEV's overall revenues, it is strategically placed for future expansion. Future...

Continue Reading